ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology development company that also provides contracted preclinical research services.
This post is an original post by ScienceDaily: Skin Care News